Search

Your search keyword '"Burgues, O."' showing total 102 results
Start Over Author "Burgues, O."
102 results on '"Burgues, O."'

2. Image-based multiplex immune profiling of cancer tissues: translational implications. A report of the International Immuno-oncology Biomarker Working Group on Breast Cancer

Author

Jahangir, CA, Page, DB, Broeckx, G, Gonzalez, CA, Burke, C, Murphy, C, Reis-Filho, JS, Ly, A, Harms, PW, Gupta, RR, Vieth, M, Hida, A, Kahila, M, Kos, Z, van Diest, PJ, Verbandt, S, Thagaard, J, Khiroya, R, Abduljabbar, K, Haab, GA, Acs, B, Adams, S, Almeida, JS, Alvarado-Cabrero, I, Azmoudeh-Ardalan, F, Badve, S, Baharun, NB, Bellolio, ER, Bheemaraju, V, Blenman, KRM, Fujimoto, LBM, Burgues, O, Chardas, A, Cheang, MCU, Ciompi, F, Cooper, LAD, Coosemans, A, Corredor, G, Portela, FLD, Deman, F, Demaria, S, Dudgeon, SN, Elghazawy, M, Fernandez-Martin, C, Fineberg, S, Fox, SB, Giltnane, JM, Gnjatic, S, Gonzalez-Ericsson, P, Grigoriadis, A, Halama, N, Hanna, MG, Harbhajanka, A, Hart, SN, Hartman, J, Hewitt, S, Horlings, HM, Husain, Z, Irshad, S, Janssen, EAM, Kataoka, TR, Kawaguchi, K, Khramtsov, A, Kiraz, U, Kirtani, P, Kodach, LL, Korski, K, Akturk, G, Scott, E, Kovacs, A, Laenkholm, A-V, Lang-Schwarz, C, Larsimont, D, Lennerz, JK, Lerousseau, M, Li, X, Madabhushi, A, Maley, SK, Narasimhamurthy, VM, Marks, DK, McDonald, ES, Mehrotra, R, Michiels, S, Kharidehal, D, Minhas, FUAA, Mittal, S, Moore, DA, Mushtaq, S, Nighat, H, Papathomas, T, Penault-Llorca, F, Perera, RD, Pinard, CJ, Pinto-Cardenas, JC, Pruneri, G, Pusztai, L, Rajpoot, NM, Rapoport, BL, Rau, TT, Ribeiro, JM, Rimm, D, Vincent-Salomon, A, Saltz, J, Sayed, S, Hytopoulos, E, Mahon, S, Siziopikou, KP, Sotiriou, C, Stenzinger, A, Sughayer, MA, Sur, D, Symmans, F, Tanaka, S, Taxter, T, Tejpar, S, Teuwen, J, Thompson, EA, Tramm, T, Tran, WT, van Der Laak, J, Verghese, GE, Viale, G, Wahab, N, Walter, T, Waumans, Y, Wen, HY, Yang, W, Yuan, Y, Bartlett, J, Loibl, S, Denkert, C, Savas, P, Loi, S, Stovgaard, ES, Salgado, R, Gallagher, WM, Rahman, A, Jahangir, CA, Page, DB, Broeckx, G, Gonzalez, CA, Burke, C, Murphy, C, Reis-Filho, JS, Ly, A, Harms, PW, Gupta, RR, Vieth, M, Hida, A, Kahila, M, Kos, Z, van Diest, PJ, Verbandt, S, Thagaard, J, Khiroya, R, Abduljabbar, K, Haab, GA, Acs, B, Adams, S, Almeida, JS, Alvarado-Cabrero, I, Azmoudeh-Ardalan, F, Badve, S, Baharun, NB, Bellolio, ER, Bheemaraju, V, Blenman, KRM, Fujimoto, LBM, Burgues, O, Chardas, A, Cheang, MCU, Ciompi, F, Cooper, LAD, Coosemans, A, Corredor, G, Portela, FLD, Deman, F, Demaria, S, Dudgeon, SN, Elghazawy, M, Fernandez-Martin, C, Fineberg, S, Fox, SB, Giltnane, JM, Gnjatic, S, Gonzalez-Ericsson, P, Grigoriadis, A, Halama, N, Hanna, MG, Harbhajanka, A, Hart, SN, Hartman, J, Hewitt, S, Horlings, HM, Husain, Z, Irshad, S, Janssen, EAM, Kataoka, TR, Kawaguchi, K, Khramtsov, A, Kiraz, U, Kirtani, P, Kodach, LL, Korski, K, Akturk, G, Scott, E, Kovacs, A, Laenkholm, A-V, Lang-Schwarz, C, Larsimont, D, Lennerz, JK, Lerousseau, M, Li, X, Madabhushi, A, Maley, SK, Narasimhamurthy, VM, Marks, DK, McDonald, ES, Mehrotra, R, Michiels, S, Kharidehal, D, Minhas, FUAA, Mittal, S, Moore, DA, Mushtaq, S, Nighat, H, Papathomas, T, Penault-Llorca, F, Perera, RD, Pinard, CJ, Pinto-Cardenas, JC, Pruneri, G, Pusztai, L, Rajpoot, NM, Rapoport, BL, Rau, TT, Ribeiro, JM, Rimm, D, Vincent-Salomon, A, Saltz, J, Sayed, S, Hytopoulos, E, Mahon, S, Siziopikou, KP, Sotiriou, C, Stenzinger, A, Sughayer, MA, Sur, D, Symmans, F, Tanaka, S, Taxter, T, Tejpar, S, Teuwen, J, Thompson, EA, Tramm, T, Tran, WT, van Der Laak, J, Verghese, GE, Viale, G, Wahab, N, Walter, T, Waumans, Y, Wen, HY, Yang, W, Yuan, Y, Bartlett, J, Loibl, S, Denkert, C, Savas, P, Loi, S, Stovgaard, ES, Salgado, R, Gallagher, WM, and Rahman, A

Published
2024

4. 74P Transcriptomic profile identifies biological differences in very young women with breast cancer

Author

Garrido-Cano, I., primary, Céspedes, M. Tapia, additional, Carbonell-Asins, J.A., additional, Peña, C., additional, Burgues, O., additional, Tebar, C., additional, Terrádez, L., additional, Àgreda-Roca, A., additional, Torres, S., additional, Segui-Manzaneque, V., additional, Grimalt, N., additional, Bartolomé, M.G., additional, Melia, C. Hernando, additional, Rentero-Garrido, P., additional, Buch, E., additional, Lluch, A., additional, Gonzalez, I. Chirivella, additional, Bermejo, B., additional, Martinez, M.T.M., additional, and Cejalvo, J.M., additional

Published
2023
Full Text
View/download PDF

7. Pitfalls in machine learning-based assessment of tumor-infiltrating lymphocytes in breast cancer: a report of the international immuno-oncology biomarker working group

Author

Thagaard, J, Broeckx, G, Page, DB, Jahangir, CA, Verbandt, S, Kos, Z, Gupta, R, Khiroya, R, Abduljabbar, K, Acosta Haab, G, Acs, B, Akturk, G, Almeida, JS, Alvarado-Cabrero, I, Amgad, M, Azmoudeh-Ardalan, F, Badve, S, Baharun, NB, Balslev, E, Bellolio, ER, Bheemaraju, V, Blenman, KRM, Botinelly Mendonca Fujimoto, L, Bouchmaa, N, Burgues, O, Chardas, A, Cheang, MU, Ciompi, F, Cooper, LAD, Coosemans, A, Corredor, G, Dahl, AB, Dantas Portela, FL, Deman, F, Demaria, S, Dore Hansen, J, Dudgeon, SN, Ebstrup, T, Elghazawy, M, Fernandez-Martin, C, Fox, SB, Gallagher, WM, Giltnane, JM, Gnjatic, S, Gonzalez-Ericsson, P, Grigoriadis, A, Halama, N, Hanna, MG, Harbhajanka, A, Hart, SN, Hartman, J, Hauberg, S, Hewitt, S, Hida, A, Horlings, HM, Husain, Z, Hytopoulos, E, Irshad, S, Janssen, EAM, Kahila, M, Kataoka, TR, Kawaguchi, K, Kharidehal, D, Khramtsov, A, Kiraz, U, Kirtani, P, Kodach, LL, Korski, K, Kovacs, A, Laenkholm, A-V, Lang-Schwarz, C, Larsimont, D, Lennerz, JK, Lerousseau, M, Li, X, Ly, A, Madabhushi, A, Maley, SK, Manur Narasimhamurthy, V, Marks, DK, McDonald, ES, Mehrotra, R, Michiels, S, Minhas, FUAA, Mittal, S, Moore, DA, Mushtaq, S, Nighat, H, Papathomas, T, Penault-Llorca, F, Perera, RD, Pinard, CJ, Pinto-Cardenas, JC, Pruneri, G, Pusztai, L, Rahman, A, Rajpoot, NM, Rapoport, BL, Rau, TT, Reis-Filho, JS, Ribeiro, JM, Rimm, D, Roslind, A, Vincent-Salomon, A, Salto-Tellez, M, Saltz, J, Sayed, S, Scott, E, Siziopikou, KP, Sotiriou, C, Stenzinger, A, Sughayer, MA, Sur, D, Fineberg, S, Symmans, F, Tanaka, S, Taxter, T, Tejpar, S, Teuwen, J, Thompson, EA, Tramm, T, Tran, WT, van Der Laak, J, van Diest, PJ, Verghese, GE, Viale, G, Vieth, M, Wahab, N, Walter, T, Waumans, Y, Wen, HY, Yang, W, Yuan, Y, Zin, RM, Adams, S, Bartlett, J, Loibl, S, Denkert, C, Savas, P, Loi, S, Salgado, R, Specht Stovgaard, E, Thagaard, J, Broeckx, G, Page, DB, Jahangir, CA, Verbandt, S, Kos, Z, Gupta, R, Khiroya, R, Abduljabbar, K, Acosta Haab, G, Acs, B, Akturk, G, Almeida, JS, Alvarado-Cabrero, I, Amgad, M, Azmoudeh-Ardalan, F, Badve, S, Baharun, NB, Balslev, E, Bellolio, ER, Bheemaraju, V, Blenman, KRM, Botinelly Mendonca Fujimoto, L, Bouchmaa, N, Burgues, O, Chardas, A, Cheang, MU, Ciompi, F, Cooper, LAD, Coosemans, A, Corredor, G, Dahl, AB, Dantas Portela, FL, Deman, F, Demaria, S, Dore Hansen, J, Dudgeon, SN, Ebstrup, T, Elghazawy, M, Fernandez-Martin, C, Fox, SB, Gallagher, WM, Giltnane, JM, Gnjatic, S, Gonzalez-Ericsson, P, Grigoriadis, A, Halama, N, Hanna, MG, Harbhajanka, A, Hart, SN, Hartman, J, Hauberg, S, Hewitt, S, Hida, A, Horlings, HM, Husain, Z, Hytopoulos, E, Irshad, S, Janssen, EAM, Kahila, M, Kataoka, TR, Kawaguchi, K, Kharidehal, D, Khramtsov, A, Kiraz, U, Kirtani, P, Kodach, LL, Korski, K, Kovacs, A, Laenkholm, A-V, Lang-Schwarz, C, Larsimont, D, Lennerz, JK, Lerousseau, M, Li, X, Ly, A, Madabhushi, A, Maley, SK, Manur Narasimhamurthy, V, Marks, DK, McDonald, ES, Mehrotra, R, Michiels, S, Minhas, FUAA, Mittal, S, Moore, DA, Mushtaq, S, Nighat, H, Papathomas, T, Penault-Llorca, F, Perera, RD, Pinard, CJ, Pinto-Cardenas, JC, Pruneri, G, Pusztai, L, Rahman, A, Rajpoot, NM, Rapoport, BL, Rau, TT, Reis-Filho, JS, Ribeiro, JM, Rimm, D, Roslind, A, Vincent-Salomon, A, Salto-Tellez, M, Saltz, J, Sayed, S, Scott, E, Siziopikou, KP, Sotiriou, C, Stenzinger, A, Sughayer, MA, Sur, D, Fineberg, S, Symmans, F, Tanaka, S, Taxter, T, Tejpar, S, Teuwen, J, Thompson, EA, Tramm, T, Tran, WT, van Der Laak, J, van Diest, PJ, Verghese, GE, Viale, G, Vieth, M, Wahab, N, Walter, T, Waumans, Y, Wen, HY, Yang, W, Yuan, Y, Zin, RM, Adams, S, Bartlett, J, Loibl, S, Denkert, C, Savas, P, Loi, S, Salgado, R, and Specht Stovgaard, E

Published
2023

8. Spatial analyses of immune cell infiltration in cancer: current methods and future directions. A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer

Author

Page, DB, Broeckx, G, Jahangir, CA, Jahangir, C, Verbandt, S, Gupta, RR, Thagaard, J, Khiroya, R, Kos, Z, Abduljabbar, K, Acosta Haab, G, Acs, B, Almeida, JS, Alvarado-Cabrero, I, Azmoudeh-Ardalan, F, Badve, S, Baharun, NB, Bellolio, ER, Bheemaraju, V, Blenman, KRM, Botinelly Mendonca Fujimoto, L, Burgues, O, Cheang, MCU, Ciompi, F, Cooper, LAD, Coosemans, A, Corredor, G, Dantas Portela, FL, Deman, F, Demaria, S, Dudgeon, SN, Elghazawy, M, Ely, S, Fernandez-Martin, C, Fineberg, S, Fox, SB, Gallagher, WM, Giltnane, JM, Gnjatic, S, Gonzalez-Ericsson, P, Grigoriadis, A, Halama, N, Hanna, MG, Harbhajanka, A, Hardas, A, Hart, SN, Hartman, J, Hewitt, S, Hida, A, Horlings, HM, Husain, Z, Hytopoulos, E, Irshad, S, Janssen, EAM, Kahila, M, Kataoka, TR, Kawaguchi, K, Kharidehal, D, Khramtsov, A, Kiraz, U, Kirtani, P, Kodach, LL, Korski, K, Kovacs, A, Laenkholm, A-V, Lang-Schwarz, C, Larsimont, D, Lennerz, JK, Lerousseau, M, Li, X, Ly, A, Madabhushi, A, Maley, SK, Manur Narasimhamurthy, V, Marks, DK, McDonald, ES, Mehrotra, R, Michiels, S, Minhas, FUAA, Mittal, S, Moore, DA, Mushtaq, S, Nighat, H, Papathomas, T, Penault-Llorca, F, Perera, RD, Pinard, CJ, Pinto-Cardenas, JC, Pruneri, G, Pusztai, L, Rahman, A, Rajpoot, NM, Rapoport, BL, Rau, TT, Reis-Filho, JS, Ribeiro, JM, Rimm, D, Salomon, A-V, Salto-Tellez, M, Saltz, J, Sayed, S, Siziopikou, KP, Sotiriou, C, Stenzinger, A, Sughayer, MA, Sur, D, Symmans, F, Tanaka, S, Taxter, T, Tejpar, S, Teuwen, J, Thompson, EA, Tramm, T, Tran, WT, van Der Laak, J, van Diest, PJ, Verghese, GE, Viale, G, Vieth, M, Wahab, N, Walter, T, Waumans, Y, Wen, HY, Yang, W, Yuan, Y, Adams, S, Bartlett, JMS, Loibl, S, Denkert, C, Savas, P, Loi, S, Salgado, R, Specht Stovgaard, E, Akturk, G, Bouchmaa, N, Page, DB, Broeckx, G, Jahangir, CA, Jahangir, C, Verbandt, S, Gupta, RR, Thagaard, J, Khiroya, R, Kos, Z, Abduljabbar, K, Acosta Haab, G, Acs, B, Almeida, JS, Alvarado-Cabrero, I, Azmoudeh-Ardalan, F, Badve, S, Baharun, NB, Bellolio, ER, Bheemaraju, V, Blenman, KRM, Botinelly Mendonca Fujimoto, L, Burgues, O, Cheang, MCU, Ciompi, F, Cooper, LAD, Coosemans, A, Corredor, G, Dantas Portela, FL, Deman, F, Demaria, S, Dudgeon, SN, Elghazawy, M, Ely, S, Fernandez-Martin, C, Fineberg, S, Fox, SB, Gallagher, WM, Giltnane, JM, Gnjatic, S, Gonzalez-Ericsson, P, Grigoriadis, A, Halama, N, Hanna, MG, Harbhajanka, A, Hardas, A, Hart, SN, Hartman, J, Hewitt, S, Hida, A, Horlings, HM, Husain, Z, Hytopoulos, E, Irshad, S, Janssen, EAM, Kahila, M, Kataoka, TR, Kawaguchi, K, Kharidehal, D, Khramtsov, A, Kiraz, U, Kirtani, P, Kodach, LL, Korski, K, Kovacs, A, Laenkholm, A-V, Lang-Schwarz, C, Larsimont, D, Lennerz, JK, Lerousseau, M, Li, X, Ly, A, Madabhushi, A, Maley, SK, Manur Narasimhamurthy, V, Marks, DK, McDonald, ES, Mehrotra, R, Michiels, S, Minhas, FUAA, Mittal, S, Moore, DA, Mushtaq, S, Nighat, H, Papathomas, T, Penault-Llorca, F, Perera, RD, Pinard, CJ, Pinto-Cardenas, JC, Pruneri, G, Pusztai, L, Rahman, A, Rajpoot, NM, Rapoport, BL, Rau, TT, Reis-Filho, JS, Ribeiro, JM, Rimm, D, Salomon, A-V, Salto-Tellez, M, Saltz, J, Sayed, S, Siziopikou, KP, Sotiriou, C, Stenzinger, A, Sughayer, MA, Sur, D, Symmans, F, Tanaka, S, Taxter, T, Tejpar, S, Teuwen, J, Thompson, EA, Tramm, T, Tran, WT, van Der Laak, J, van Diest, PJ, Verghese, GE, Viale, G, Vieth, M, Wahab, N, Walter, T, Waumans, Y, Wen, HY, Yang, W, Yuan, Y, Adams, S, Bartlett, JMS, Loibl, S, Denkert, C, Savas, P, Loi, S, Salgado, R, Specht Stovgaard, E, Akturk, G, and Bouchmaa, N

Published
2023

9. Pitfalls in machine learning-based assessment of tumor-infiltrating lymphocytes in breast cancer: a report of the international immuno-oncology biomarker working group.

Author

Thagaard, J., Broeckx, G., Page, D.B., Jahangir, C.A., Verbandt, S., Kos, Z., Gupta, R., Khiroya, R., AbdulJabbar, K., Haab, G.A., Acs, B., Akturk, G., Almeida, J.S., Alvarado-Cabrero, I., Amgad, M., Azmoudeh-Ardalan, F., Badve, S., Baharun, N.B., Balslev, E., Bellolio, E.R., Bheemaraju, V., Blenman, K.R., Botinelly Mendonça Fujimoto, L., Bouchmaa, N., Burgues, O., Chardas, A., Chon U Cheang, M., Ciompi, F., Cooper, L.A., Coosemans, A., Corredor, G., Dahl, A.B., Dantas Portela, F.L., Deman, F., Demaria, S., Doré Hansen, J., Dudgeon, S.N., Ebstrup, T., Elghazawy, M., Fernandez-Martín, C., Fox, S.B., Gallagher, W.M., Giltnane, J.M., Gnjatic, S., Gonzalez-Ericsson, P.I., Grigoriadis, A., Halama, N., Hanna, M.G., Harbhajanka, A., Hart, S.N., Hartman, J., Hauberg, S., Hewitt, S., Hida, A.I., Horlings, H.M., Husain, Z., Hytopoulos, E., Irshad, S., Janssen, E.a, Kahila, M., Kataoka, T.R., Kawaguchi, K., Kharidehal, D., Khramtsov, A.I., Kiraz, U., Kirtani, P., Kodach, L.L., Korski, K., Kovács, A., Laenkholm, A.V., Lang-Schwarz, C., Larsimont, D., Lennerz, J.K., Lerousseau, M., Li, Xiaoxian, Ly, Amy, Madabhushi, A., Maley, S.K., Manur Narasimhamurthy, V., Marks, D.K., McDonald, E.S., Mehrotra, R., Michiels, S., Minhas, F.U.A.A., Mittal, S., Moore, D.A., Mushtaq, S., Nighat, H., Papathomas, T., Penault-Llorca, F., Perera, R.D., Pinard, C.J., Pinto-Cardenas, J.C., Pruneri, G., Pusztai, L., Rahman, A., Rajpoot, N.M., Rapoport, B.L., Rau, T.T., Reis-Filho, J.S., Ribeiro, J.M., Rimm, D., Roslind, A., Vincent-Salomon, A., Salto-Tellez, M., Saltz, J., Sayed, S., Scott, E., Siziopikou, K.P., Sotiriou, C., Stenzinger, A., Sughayer, M.A., Sur, D., Fineberg, S., Symmans, F., Tanaka, S., Taxter, T., Tejpar, S., Teuwen, J., Thompson, E.A., Tramm, T., Tran, W.T., Laak, J.A.W.M. van der, Diest, P.J. van, Verghese, G.E., Viale, G., Vieth, M., Wahab, N., Walter, T., Waumans, Y., Wen, H.Y., Yang, W, Yuan, Y., Zin, R.M., Adams, S., Bartlett, J., Loibl, S., Denkert, C., Savas, P., Loi, S., Salgado, R., Specht Stovgaard, E., Thagaard, J., Broeckx, G., Page, D.B., Jahangir, C.A., Verbandt, S., Kos, Z., Gupta, R., Khiroya, R., AbdulJabbar, K., Haab, G.A., Acs, B., Akturk, G., Almeida, J.S., Alvarado-Cabrero, I., Amgad, M., Azmoudeh-Ardalan, F., Badve, S., Baharun, N.B., Balslev, E., Bellolio, E.R., Bheemaraju, V., Blenman, K.R., Botinelly Mendonça Fujimoto, L., Bouchmaa, N., Burgues, O., Chardas, A., Chon U Cheang, M., Ciompi, F., Cooper, L.A., Coosemans, A., Corredor, G., Dahl, A.B., Dantas Portela, F.L., Deman, F., Demaria, S., Doré Hansen, J., Dudgeon, S.N., Ebstrup, T., Elghazawy, M., Fernandez-Martín, C., Fox, S.B., Gallagher, W.M., Giltnane, J.M., Gnjatic, S., Gonzalez-Ericsson, P.I., Grigoriadis, A., Halama, N., Hanna, M.G., Harbhajanka, A., Hart, S.N., Hartman, J., Hauberg, S., Hewitt, S., Hida, A.I., Horlings, H.M., Husain, Z., Hytopoulos, E., Irshad, S., Janssen, E.a, Kahila, M., Kataoka, T.R., Kawaguchi, K., Kharidehal, D., Khramtsov, A.I., Kiraz, U., Kirtani, P., Kodach, L.L., Korski, K., Kovács, A., Laenkholm, A.V., Lang-Schwarz, C., Larsimont, D., Lennerz, J.K., Lerousseau, M., Li, Xiaoxian, Ly, Amy, Madabhushi, A., Maley, S.K., Manur Narasimhamurthy, V., Marks, D.K., McDonald, E.S., Mehrotra, R., Michiels, S., Minhas, F.U.A.A., Mittal, S., Moore, D.A., Mushtaq, S., Nighat, H., Papathomas, T., Penault-Llorca, F., Perera, R.D., Pinard, C.J., Pinto-Cardenas, J.C., Pruneri, G., Pusztai, L., Rahman, A., Rajpoot, N.M., Rapoport, B.L., Rau, T.T., Reis-Filho, J.S., Ribeiro, J.M., Rimm, D., Roslind, A., Vincent-Salomon, A., Salto-Tellez, M., Saltz, J., Sayed, S., Scott, E., Siziopikou, K.P., Sotiriou, C., Stenzinger, A., Sughayer, M.A., Sur, D., Fineberg, S., Symmans, F., Tanaka, S., Taxter, T., Tejpar, S., Teuwen, J., Thompson, E.A., Tramm, T., Tran, W.T., Laak, J.A.W.M. van der, Diest, P.J. van, Verghese, G.E., Viale, G., Vieth, M., Wahab, N., Walter, T., Waumans, Y., Wen, H.Y., Yang, W, Yuan, Y., Zin, R.M., Adams, S., Bartlett, J., Loibl, S., Denkert, C., Savas, P., Loi, S., Salgado, R., and Specht Stovgaard, E.

Abstract

01 augustus 2023, Contains fulltext : 296181.pdf (Publisher’s version ) (Open Access), The clinical significance of the tumor-immune interaction in breast cancer is now established, and tumor-infiltrating lymphocytes (TILs) have emerged as predictive and prognostic biomarkers for patients with triple-negative (estrogen receptor, progesterone receptor, and HER2-negative) breast cancer and HER2-positive breast cancer. How computational assessments of TILs might complement manual TIL assessment in trial and daily practices is currently debated. Recent efforts to use machine learning (ML) to automatically evaluate TILs have shown promising results. We review state-of-the-art approaches and identify pitfalls and challenges of automated TIL evaluation by studying the root cause of ML discordances in comparison to manual TIL quantification. We categorize our findings into four main topics: (1) technical slide issues, (2) ML and image analysis aspects, (3) data challenges, and (4) validation issues. The main reason for discordant assessments is the inclusion of false-positive areas or cells identified by performance on certain tissue patterns or design choices in the computational implementation. To aid the adoption of ML for TIL assessment, we provide an in-depth discussion of ML and image analysis, including validation issues that need to be considered before reliable computational reporting of TILs can be incorporated into the trial and routine clinical management of patients with triple-negative breast cancer. © 2023 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

Published
2023

10. Spatial analyses of immune cell infiltration in cancer: current methods and future directions. A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer.

Author

Page, D.B., Broeckx, G., Jahangir, C.A., Verbandt, S., Gupta, R.R., Thagaard, J., Khiroya, R., Kos, Z., AbdulJabbar, K., Acosta Haab, G., Acs, B., Akturk, G., Almeida, J.S., Alvarado-Cabrero, I., Azmoudeh-Ardalan, F., Badve, S., Baharun, N.B., Bellolio, E.R., Bheemaraju, V., Blenman, K.R., Botinelly Mendonça Fujimoto, L., Bouchmaa, N., Burgues, O., Cheang, M.C.U., Ciompi, F., Cooper, L.A., Coosemans, A., Corredor, G., Dantas Portela, F.L., Deman, F., Demaria, S., Dudgeon, S.N., Elghazawy, M., Ely, S., Fernandez-Martín, C., Fineberg, S., Fox, S.B., Gallagher, W.M., Giltnane, J.M., Gnjatic, S., Gonzalez-Ericsson, P.I., Grigoriadis, A., Halama, N., Hanna, M.G., Harbhajanka, A., Hardas, A., Hart, S.N., Hartman, J., Hewitt, S., Hida, A.I., Horlings, H.M., Husain, Z., Hytopoulos, E., Irshad, S., Janssen, E.a, Kahila, M., Kataoka, T.R., Kawaguchi, K., Kharidehal, D., Khramtsov, A.I., Kiraz, U., Kirtani, P., Kodach, L.L., Korski, K., Kovács, A., Laenkholm, A.V., Lang-Schwarz, C., Larsimont, D., Lennerz, J.K., Lerousseau, M., Li, Xiaoxian, Ly, Amy, Madabhushi, A., Maley, S.K., Manur Narasimhamurthy, V., Marks, D.K., McDonald, E.S., Mehrotra, R., Michiels, S., Minhas, F.U.A.A., Mittal, S., Moore, D.A., Mushtaq, S., Nighat, H., Papathomas, T., Penault-Llorca, F., Perera, R.D., Pinard, C.J., Pinto-Cardenas, J.C., Pruneri, G., Pusztai, L., Rahman, A., Rajpoot, N.M., Rapoport, B.L., Rau, T.T., Reis-Filho, J.S., Ribeiro, J.M., Rimm, D., Vincent-Salomon, A., Salto-Tellez, M., Saltz, J., Sayed, S., Siziopikou, K.P., Sotiriou, C., Stenzinger, A., Sughayer, M.A., Sur, D., Symmans, F., Tanaka, S., Taxter, T., Tejpar, S., Teuwen, J., Thompson, E.A., Tramm, T., Tran, W.T., Laak, J.A.W.M. van der, Diest, P.J. van, Verghese, G.E., Viale, G., Vieth, M., Wahab, N., Walter, T., Waumans, Y., Wen, H.Y., Yang, W, Yuan, Y., Adams, S., Bartlett, J.M.S., Loibl, S., Denkert, C., Savas, P., Loi, S., Salgado, R., Specht Stovgaard, E., Page, D.B., Broeckx, G., Jahangir, C.A., Verbandt, S., Gupta, R.R., Thagaard, J., Khiroya, R., Kos, Z., AbdulJabbar, K., Acosta Haab, G., Acs, B., Akturk, G., Almeida, J.S., Alvarado-Cabrero, I., Azmoudeh-Ardalan, F., Badve, S., Baharun, N.B., Bellolio, E.R., Bheemaraju, V., Blenman, K.R., Botinelly Mendonça Fujimoto, L., Bouchmaa, N., Burgues, O., Cheang, M.C.U., Ciompi, F., Cooper, L.A., Coosemans, A., Corredor, G., Dantas Portela, F.L., Deman, F., Demaria, S., Dudgeon, S.N., Elghazawy, M., Ely, S., Fernandez-Martín, C., Fineberg, S., Fox, S.B., Gallagher, W.M., Giltnane, J.M., Gnjatic, S., Gonzalez-Ericsson, P.I., Grigoriadis, A., Halama, N., Hanna, M.G., Harbhajanka, A., Hardas, A., Hart, S.N., Hartman, J., Hewitt, S., Hida, A.I., Horlings, H.M., Husain, Z., Hytopoulos, E., Irshad, S., Janssen, E.a, Kahila, M., Kataoka, T.R., Kawaguchi, K., Kharidehal, D., Khramtsov, A.I., Kiraz, U., Kirtani, P., Kodach, L.L., Korski, K., Kovács, A., Laenkholm, A.V., Lang-Schwarz, C., Larsimont, D., Lennerz, J.K., Lerousseau, M., Li, Xiaoxian, Ly, Amy, Madabhushi, A., Maley, S.K., Manur Narasimhamurthy, V., Marks, D.K., McDonald, E.S., Mehrotra, R., Michiels, S., Minhas, F.U.A.A., Mittal, S., Moore, D.A., Mushtaq, S., Nighat, H., Papathomas, T., Penault-Llorca, F., Perera, R.D., Pinard, C.J., Pinto-Cardenas, J.C., Pruneri, G., Pusztai, L., Rahman, A., Rajpoot, N.M., Rapoport, B.L., Rau, T.T., Reis-Filho, J.S., Ribeiro, J.M., Rimm, D., Vincent-Salomon, A., Salto-Tellez, M., Saltz, J., Sayed, S., Siziopikou, K.P., Sotiriou, C., Stenzinger, A., Sughayer, M.A., Sur, D., Symmans, F., Tanaka, S., Taxter, T., Tejpar, S., Teuwen, J., Thompson, E.A., Tramm, T., Tran, W.T., Laak, J.A.W.M. van der, Diest, P.J. van, Verghese, G.E., Viale, G., Vieth, M., Wahab, N., Walter, T., Waumans, Y., Wen, H.Y., Yang, W, Yuan, Y., Adams, S., Bartlett, J.M.S., Loibl, S., Denkert, C., Savas, P., Loi, S., Salgado, R., and Specht Stovgaard, E.

Abstract

01 augustus 2023, Contains fulltext : 296131.pdf (Publisher’s version ) (Closed access), Modern histologic imaging platforms coupled with machine learning methods have provided new opportunities to map the spatial distribution of immune cells in the tumor microenvironment. However, there exists no standardized method for describing or analyzing spatial immune cell data, and most reported spatial analyses are rudimentary. In this review, we provide an overview of two approaches for reporting and analyzing spatial data (raster versus vector-based). We then provide a compendium of spatial immune cell metrics that have been reported in the literature, summarizing prognostic associations in the context of a variety of cancers. We conclude by discussing two well-described clinical biomarkers, the breast cancer stromal tumor infiltrating lymphocytes score and the colon cancer Immunoscore, and describe investigative opportunities to improve clinical utility of these spatial biomarkers. © 2023 The Pathological Society of Great Britain and Ireland.

Published
2023

12. 281P Prevalence of HER2-low breast cancer in the GEICAM/2011-06 trial: Agreement in HER2-low classification between standardized immunohistochemistry assays

Author

Rojo, F., Calvo-Martinez, L., B. bermejo, Bernet, L., Burgués, O., García-Caballero, T., Lopez-Tarruella Cobo, S., Pérez, S., Antolín-Novoa, S., Cejalvo, J.M., Gilarranz, Y. Jerez, Estevez, C. Morales, Rendo, C. Reboredo, Martinez, M.T.M., Herranz, J., Sánchez, R. Rincón, Caballero, R., Barnadas, A., De la Haba Rodriguez, J., and Jimenez, M. Martin

Published
2024
Full Text
View/download PDF

13. 280P Personalized treatment approaches with HER2DX in early HER2-positive breast cancer: A precision tool for treatment decision-making

Author

Céspedes, M. Tapia, Cussac, A. Llombart, Tebar, C., Liebana, S.M., Molina, A. Magro, Abad, L. Palomar, Martinez, M.T.M., Melia, C. Hernando, Iranzo, V., Pouptsis, A., Bertran, A. Santaballa, Torregrosa Maicas, M.D., Burgués, O., Cano, I. Garrido, Lluch-Hernandez, A., Gonzalez, P. Villagrasa, Prat, A., bermejo, B., and Cejalvo, J.M.

Published
2024
Full Text
View/download PDF

14. Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer

Author

Albanell, J., González, A., Ruiz-Borrego, M., Alba, E., García-Saenz, J.A., Corominas, J.M., Burgues, O., Furio, V., Rojo, A., Palacios, J., Bermejo, B., Martínez-García, M., Limon, M.L., Muñoz, A.S., Martín, M., Tusquets, I., Rojo, F., Colomer, R., Faull, I., and Lluch, A.

Published
2012
Full Text
View/download PDF

15. Histological Grade and Tumor Stage Are Correlated with Expression of Receptor Activator of Nuclear Factor Kappa b (Rank) in Epithelial Ovarian Cancers

Author

Gomez R, Tejada M, Rodriguez-Garcia V, Burgues O, Santos-Llamas A, Martinez-Massa A, Marin-Montes A, Tarin J, and Cano A

Abstract

The receptor activator of nuclear factor kappa B (RANK) is becoming recognized as a master regulator of tumorigenesis, yet its role in gynecological cancers remains mostly unexplored. We investigated whether there is a gradation of RANK protein and mRNA expression in epithelial ovarian cancer (EOC) according to malignancy and tumor staging. Immunohistochemical expression of RANK was examined in a cohort of 135 (benign n = 29, borderline n= 23 and malignant n = 83) EOCs. Wild type and truncated RANK mRNA isoform quantification was performed in a cohort of 168 (benign n = 26, borderline n = 13 and malignant n = 129) EOCs. RANK protein and mRNA values were increased in malignant vs. benign or borderline conditions across serous, mucinous and endometrioid cancer subtypes. Additionally, a trend of increased RANK values with staging was observed for the mucinous and serous histotype. Thus, increased expression of RANK appears associated with the evolution of disease to the onset of malignancy in EOC. Moreover, in some EOC histotypes, RANK expression is additionally associated with clinicopathological markers of tumor aggressiveness, suggesting a role in further progression of tumor activity.

Published
2022

16. Is Axillary Assessment of Ductal Carcinoma In Situ of the Breast Necessary in All Cases?

Author

Bellver G, Buch E, Ripoll F, Adrianzen M, Bermejo B, Burgues O, Julve A, and Ortega J

Subjects
skin and connective tissue diseases
Abstract

BACKGROUND: Staging of the axilla in women with ductal carcinoma in situ (DCIS) is a point of controversy. We aimed to assess whether there is a group of patients in whom axillary assessment can be avoided and whether the likelihood of underdiagnosis of infiltrating carcinoma is sufficient to justify this evaluation. MATERIALS AND METHODS: This was a multicenter, prospective, observational study of patients who were operated on between 2008 and 2018 in three Spanish hospitals, with a diagnosis by radiological or excisional biopsy of DCIS and clinically and radiologically negative axilla. RESULTS: A total of 530 patients with a preoperative diagnosis of DCIS were studied. An axillary assessment was performed in 77% of the patients. In 397 patients, selective sentinel lymph node biopsy was performed. Axillary involvement was found in 7.2% of all patients, which dropped to 2.15% if we only included DCIS diagnosed after a definitive anatomical pathology analysis. Underdiagnosis was correlated with the type of biopsy performed: the risk was 1.34 times as high if the biopsy was performed with a core needle. The risk of lymph node metastasis was higher when there was lymphovascular invasion and when mastectomy was performed. CONCLUSIONS: We propose an axilla management algorithm in patients with a preoperative diagnosis of DCIS. The patients who would benefit from sentinel lymph node biopsy would be those who are not candidates for breast-conserving surgery, those with a BIRADS 5 lesion biopsied by core-needle biopsy, and those whose definitive diagnosis is lymphovascular invasion. (C) 2021 Elsevier Inc. All rights reserved.

Published
2022

17. Targeted immunotherapy against distinct cancer-associated fibroblasts overcomes treatment resistance in refractory HER2+breast tumors

Author

Rivas E, Linares J, Zwick M, Gomez-Llonin A, Guiu M, Labernadie A, Badia-Ramentol J, Llado A, Bardia L, Perez-Nunez I, Martinez-Ciarpaglini C, Tarazona N, Sallent-Aragay A, Garrido M, Celia-Terrassa T, Burgues O, Gomis R, Albanell J, and Calon A

Abstract

A substantial proportion of HER2+ breast cancer patients do not benefit from HER2-targeted therapy. Here, the authors identify a population of cancer-associated fibroblasts involved in the suppression of trastuzumab-induced ADCC that can be pharmacologically targeted to raise treatment effectiveness in unresponsive tumors. About 50% of human epidermal growth factor receptor 2 (HER2)+ breast cancer patients do not benefit from HER2-targeted therapy and almost 20% of them relapse after treatment. Here, we conduct a detailed analysis of two independent cohorts of HER2+ breast cancer patients treated with trastuzumab to elucidate the mechanisms of resistance to anti-HER2 monoclonal antibodies. In addition, we develop a fully humanized immunocompetent model of HER2+ breast cancer recapitulating ex vivo the biological processes that associate with patients' response to treatment. Thanks to these two approaches, we uncover a population of TGF-beta-activated cancer-associated fibroblasts (CAF) specific from tumors resistant to therapy. The presence of this cellular subset related to previously described myofibroblastic (CAF-S1) and podoplanin+ CAF subtypes in breast cancer associates with low IL2 activity. Correspondingly, we find that stroma-targeted stimulation of IL2 pathway in unresponsive tumors restores trastuzumab anti-cancer efficiency. Overall, our study underscores the therapeutic potential of exploiting the tumor microenvironment to identify and overcome mechanisms of resistance to anti-cancer treatment.

Published
2022

18. Aurora kinases in ovarian cancer

Author

Perez-Fidalgo J, Gambardella V, Pineda B, Burgues O, Pinero O, and Cervantes A

Abstract

Aurora kinases (AURK) are key regulators of the mitotic spindle formation. AURK is frequently overexpressed in ovarian cancer and this overexpression has been frequently associated with prognosis in these tumours. Interestingly, AURK have been shown to interact with DNA repair mechanisms and other cell cycle regulators. These functions have brought light to Aurora family as a potential target for anticancer therapy. In the last years, two clinical trials with different AURK inhibitors have shown activity in epithelial and clear-cell ovarian cancer. Although there is a lack of predictive factors of AURK inhibition activity, recent trials have identified some candidates. This review will focus in the functions of the AURK family, its role as prognostic factor in epithelial ovarian cancer and potential clinical implications.

Published
2020

19. MicroRNA-33b Suppresses Epithelial-Mesenchymal Transition Repressing the MYC-EZH2 Pathway in HER2+ Breast Carcinoma

Author

Pattanayak B, Garrido-Cano I, Adam-Artigues A, Tormo E, Pineda B, Cabello P, Alonso E, Bermejo B, Hernando C, Martinez M, Rovira A, Albanell J, Rojo F, Burgues O, Cejalvo J, Lluch A, and Eroles P

Subjects
macromolecular substances
Abstract

Downregulation of miR-33b has been documented in many types of cancers and is being involved in proliferation, migration, and epithelial-mesenchymal transition (EMT). Furthermore, the enhancer of zeste homolog 2-gene (EZH2) is a master regulator of controlling the stem cell differentiation and the cell proliferation processes. We aim to evaluate the implication of miR-33b in the EMT pathway in HER2+ breast cancer (BC) and to analyze the role of EZH2 in this process as well as the interaction between them. miR-33b is downregulated in HER2+ BC cells vs healthy controls, where EZH2 has an opposite expression in vitro and in patients' samples. The upregulation of miR-33b suppressed proliferation, induced apoptosis, reduced invasion, migration and regulated EMT by an increase of E-cadherin and a decrease of SS-catenin and vimentin. The silencing of EZH2 mimicked the impact of miR-33b overexpression. Furthermore, the inhibition of miR-33b induces cell proliferation, invasion, migration, EMT, and EZH2 expression in non-tumorigenic cells. Importantly, the Kaplan-Meier analysis showed a significant association between high miR-33b expression and better overall survival. These results suggest miR-33b as a suppressive miRNA that could inhibit tumor metastasis and invasion in HER2+ BC partly by impeding EMT through the repression of the MYC-EZH2 loop.

Published
2020

21. 583P Aurora kinase overexpression may play a role in PARPi resistance in tumor samples of patients with high grade ovarian cancer and its inhibition with alisertib overcomes resistance to olaparib in a PARPi-resistant cell line model

Author

Perez Fidalgo, J.A., Martinez Pretel, J.J., Heredia, V., Romeo Marin, M., Mendiola, M., Hochstadt, J., Bernat, A., Sanchez-Serrano, P., Redondo Sanchez, A., Gil Martín, M., Guerra Ojeda, S., Teruel, I., Burgués, O., Cervantes, A., and Pineda Merlo, B.

Published
2022
Full Text
View/download PDF

23. 108P Pathologic nodal positivity in patients with cT1-2 cN0 HER2+ breast cancer treated with upfront surgery or neoadjuvant anti-HER2-based therapy

Author

Martinez Saez, O., Hernando Melia, C., Rey, M., Chic, N., Martinez, M.T.M., Cebrecos, I., Bermejo De Las Heras, B., Bargalló, X., Burgués, O., Ganau, S., Úbeda, B., Mollá, M., Vidal-Siscart, S., Sanfeliu Torres, E., Gonzalez-Farre, B., Vidal, M., Adamo, B., Munoz, M., Prat, A., and Cejalvo Andujar, J.M.

Published
2022
Full Text
View/download PDF

26. Breast Cancer in Very Young Patients in a Spanish Cohort: Age as an Independent Bad Prognostic Indicator

Author

Martinez M, Oltra S, Peña-Chilet M, Alonso E, Hernando C, Burgues O, Chirivella I, Bermejo B, Lluch A, and Ribas G

Abstract

PURPOSE: Breast cancer (BC) in very young women (BCVY) is more aggressive than in older women. The purpose of this study was to evaluate the relevance of a range of clinico-pathological factors in the prognosis of BCVY patients. METHODS: We retrospectively analyzed 258 patients diagnosed with BCVY at our hospital from 1998 to 2014; the control group comprised 101 older patients with BC. We correlated clinicopathological factors, treatments, relapse and exitus with age and with previously published miRNA expression data. RESULTS: We identified some significant differences in risk factors between BCVY and older patients. The age at menarche, number of pregnancies, and age at first pregnancy were lower in the BCVY group and had a greater probability of recurrence and death in all cases. Lymph node-positive patients in the BCVY group are associated with a worse prognosis (P = .02), an immunohistochemical HER2+ subtype, and disease relapse (P =.03). Moreover, there was a shorter time between diagnosis and first relapse in BCVY patients compared with controls, and they were more likely to die from the disease (P = .002). Finally, from our panel of miRNAs deregulated in BC, reduced miR-30c expression was associated with more aggressive BC in very young patients, lower overall survival, and with axillary lymph node metastases. CONCLUSIONS: Patient age and axillary lymph node status post-surgery are independent and significant predictors of distant disease-free survival, local recurrence-free survival, and overall survival. The HER2+ subtype and lower miR-30c expression are related to poor prognosis in lymph node-positive young BC patients.

Published
2019

27. The role of AXL as mechanism of resistance to trastuzumab and a prognostic factor in breast cancer HER2 positive: A translational approach

Author

Adam-Artigues, A., primary, Tormo, E., additional, Rojo, F., additional, Perez-Fidalgo, J.A., additional, Zazo, S., additional, Gonzalez-Alonso, P., additional, Hernando, C., additional, Martínez, M.T., additional, Gambardella, V., additional, Poveda, J., additional, Simón, S., additional, Moragon, S., additional, Alonso, E., additional, Albanell, J., additional, Burgues, O., additional, Bermejo, B., additional, Eroles, P., additional, Lluch, A., additional, Cejalvo, J.M., additional, and Rovira, A., additional

Published
2019
Full Text
View/download PDF

28. Clinical application of mutational analysis in breast cancer patients: The relevance of PIK3CA analysis for precision medicine

Author

Cejalvo, J.M., primary, Moragon, S., additional, Ortega, B., additional, Hernando, C., additional, Martínez, M., additional, Gambardella, V., additional, Tarazona Llavero, N., additional, Roda, D., additional, Burgues, O., additional, Alonso, E., additional, Simón, S., additional, Poveda, J., additional, Rentero, P., additional, Zuñiga, S., additional, Bermejo, B., additional, Lluch, A., additional, and Cervantes, A., additional

Published
2019
Full Text
View/download PDF

32. 65P Patient follow-up of NEOVATTL study

Author

Vieites, B., López-García, M.Á., Martín-Salvago, M.D., Ramírez-Tortosa, C.L., Rezola, R., Sancho de Salas, M., López Vilaró, L., Vilardell Villellas, F., Burgués, O., Fernández-Rodríguez, B., Alfaro Galán, L., and Peg, V.

Published
2021
Full Text
View/download PDF

34. Primary results of the first nationwide molecular screening program in Spain for patients with advanced breast cancer (AGATA SOLTI-1301 study)

Author

Pernas, S., primary, Villagrasa, P., additional, Vivancos, A., additional, Scaltriti, M., additional, Rodon, J., additional, Burgues, O., additional, Nuciforo, P.G., additional, Canes, J., additional, Dueñas, M., additional, Vidal, M., additional, Lluch, A., additional, Perelló, A., additional, Llombart, A., additional, Dorca, J., additional, Montaño, Á, additional, Oliveira, M., additional, Ribas, G., additional, Rapado, I., additional, Prat, A., additional, and Ciruelos, E.M., additional

Published
2018
Full Text
View/download PDF

38. Non-canonical NF-kappa B pathway activation predicts outcome in borderline oestrogen receptor positive breast carcinoma

Author

Rojo, F, Gonzalez-Perez, A, Furriol, J, Nicolau, MJ, Ferrer, J, Burgues, O, Sabbaghi, M, Gonzalez-Navarrete, I, Cristobal, I, Serrano, L, Zazo, S, Madoz, J, Servitja, S, Tusquets, I, Albanell, J, Lluch, A, Rovira, A, and Eroles, P

Subjects
breast cancer, non-canonical, NF-kappa B, ER-positive
Abstract

Background: NF-kappa B signalling appears deregulated in breast tumours. The purpose of this study was to determine whether the non-canonical NF-kappa B pathway, is activated in oestrogen receptor positive (ER+) breast cancer, to identify any correlation between its activity and the clinico-pathological phenotype and to explore whether NF-kappa B2 and RelB subunits and/or any of their target genes might be used as a predictive marker. Methods: Two independent cohorts of ER+ early breast cancer patients treated with adjuvant endocrine therapy were included in the study. Activation of RelB and NF-kappa B2 subunits was determined in a training set of 121 patients by measuring DNA-binding activities in nuclear extracts from fresh frozen specimens by an ELISA-based assay. Samples of 15 ER - breast cancer patients were also included in the study. In a large validation cohort of 207 patients, nuclear immunostaining of RelB and NF-kappa B2 on formalin-fixed paraffin-embedded specimens was performed. Statistical correlation within clinico-pathological factors, disease-free survival (DFS) and overall survival (OS) was evaluated. Publicly available gene expression and survival data have been interrogated aimed to identify target genes. Results: Activation of NF-kappa B2 and RelB was found in 53.7 and 49.2% of the 121 ER+ tumours analysed, with similar levels to ER - breast tumours analysed in parallel for comparisons. In the validation cohort, we obtained a similar proportion of cases with activation of NF-kappa B2 and RelB (59.9 and 32.4%), with a 39.6% of co-activation. Multiplexing immunofluorescence in breast cancer tissue confirmed an inverse spatial distribution of ER with NF-kappa B2 and RelB nuclear expression in tumour cells. Interestingly, NF-kappa B2 and RelB mRNA expression was inversely correlated with ER gene (ESR1) levels (P

Published
2016

39. AXL as a potential primary and secondary trastuzumab resistance mechanism in breast cancer cells with HER2 overexpression

Author

Cejalvo, J.M., primary, Tormo, E., additional, Adam, A., additional, Rojo, F., additional, Pineda, B., additional, Zazo, S., additional, Gonzalez-Alonso, P., additional, Sabbaghi, M., additional, Alonso, E., additional, Rovira, A., additional, Albanell, J., additional, Bermejo De Las Heras, B., additional, Burgues, O., additional, Lluch, A., additional, Perez Fidalgo, J.A., additional, and Eroles, P., additional

Published
2017
Full Text
View/download PDF

41. AGATA molecular screening program: Implementing precision medicine in patients with advanced breast cancer in Spain

Author

Pernas Simon, S., primary, Villagrasa Gonzalez, P., additional, Vivancos, A., additional, Prat, A., additional, Scaltriti, M., additional, Burgues, O., additional, Rodon, J., additional, Canes, J., additional, Lluch, A., additional, Llombart, A., additional, Dorca, J., additional, Perelló Martorell, A., additional, Oliveira, M., additional, Montaño, A., additional, Garcia-Estevez, L., additional, Nuciforo, P., additional, Ribas, G., additional, Rapado, I., additional, de la Pena, L., additional, and Ciruelos, E., additional

Published
2017
Full Text
View/download PDF

47. Concordance of genomic alterations between primary and recurrent breast cancer

Author

Meric-Bernstam F, Frampton GM, Ferrer-Lozano J, Yelensky R, Pérez-Fidalgo JA, Wang Y, Palmer GA, Ross JS, Miller VA, Su X, Eroles P, Barrera JA, Burgues O, Lluch AM, Zheng X, Sahin A, Stephens PJ, Mills GB, Cronin MT, and Gonzalez-Angulo AM

Abstract

There is growing interest in delivering genomically informed cancer therapy. Our aim was to determine the concordance of genomic alterations between primary and recurrent breast cancer. Targeted next-generation sequencing was performed on formalin-fixed paraffin-embedded (FFPE) samples, profiling 3,320 exons of 182 cancer-related genes plus 37 introns from 14 genes often rearranged in cancer. Point mutations, indels, copy-number alterations (CNA), and select rearrangements were assessed in 74 tumors from 43 patients (36 primary and 38 recurrence/metastases). Alterations potentially targetable with established or investigational therapeutics were considered actionable. Alterations were detected in 55 genes (mean 3.95 alterations/sample, range 1-12), including mutations in PIK3CA, TP53, ARID1A, PTEN, AKT1, NF1, FBXW7, and FGFR3 and amplifications in MCL1, CCND1, FGFR1, MYC, IGF1R, MDM2, MDM4, AKT3, CDK4, and AKT2. In 33 matched primary and recurrent tumors, 97 of 112 (86.6%) somatic mutations were concordant. Of identified CNAs, 136 of 159 (85.5%) were concordant: 37 (23.3%) were concordant, but below the reporting threshold in one of the matched samples, and 23 (14.5%) discordant. There was an increased frequency of CDK4/MDM2 amplifications in recurrences, as well as gains and losses of other actionable alterations. Forty of 43 (93%) patients had actionable alterations that could inform targeted treatment options. In conclusion, deep genomic profiling of cancer-related genes reveals potentially actionable alterations in most patients with breast cancer. Overall there was high concordance between primary and recurrent tumors. Analysis of recurrent tumors before treatment may provide additional insights, as both gains and losses of targets are observed.

Published
2014

50. 160 AKT and/or mTOR inhibition as a potential target in trastuzumab resistant breast cancer cells with MUC-4 overexpression

Author

Perez-Fidalgo, J.A., primary, Espin, E., additional, Tormo, E., additional, Pineda, B., additional, Cejalvo, J.M., additional, Sabbaghi, M.A., additional, Alonso, E., additional, Rovira, A., additional, Rojo, F., additional, Albanell, J., additional, Bermejo, B., additional, Burgues, O., additional, and Lluch, A., additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results